Loading patent…
AssigneeSchering Corporation
InventorsCARLOS O. STALGIS, JANICE K. ALBRECHT, PAUL W. GLUE
Estimating the term…
There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a therapeutically effective inducing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa, e.g. , pegylated interferon alfa-2b for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.
A method of treating patients having chronic hepatitis C infections which comprises (1) administering a therapeutically effective induction dosing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by the end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.
2 The method of claim 1, wherein the amount of ribavirin administered in the first treatment time period is from about 400 to 1600 mg per day.
A method of treating patients having chronic hepatitis C infections which comprises (1) administering in a first treatment time period of about at least about four weeks, about 400-1200 mg per day of ribavirin and about 1.5 micrograms per kilogram of pegylated interferori-alfa-2b BIW, followed by (2) administering in a second treatment time period of about up to about forty-four weeks, about 800-1200 mg per day of ribavirin and about 1.0 to 1.5 kilogram per micrograms of pegylated interferon-alfa-2b once a week.
A method of treating patients having chronic hepatitis C infections which comprises (1) administering, in a first treatment time period week of about four weeks up to about twelve weeks, about 400-1200 mg per day of ribavirin and 1.5 micrograms per kilogram of pegylated interferon-alfa-2b twice a week, followed by (2) administering, in a second treatment time period of about thirty-six up to about forty-four weeks, about 800-1200 mg per day of ribavirin and about 0.5 to 1.5 micrograms per kilogram of pegylated interferon-alfa-2b once a week(QW).
Dependencies are inferred from the claim text.